Salvatore Bongarzone
Research Subjects
Salvatore Bongarzone has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Antony D. Gee
King’s College London
24 shared publications - Paolo Carloni
RWTH Aachen University
8 shared publications - Giuseppe Legname
Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Trieste, Italy
7 shared publications Hoang Ngoc Ai Tran
Department of Comparative Biology & Experimental Medicine, University of Calgary, Calgary, Canada
6 shared publicationsMaria Laura Bolognesi
Department of Pharmacy & Biotechnology, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126Bologna, Italy
6 shared publicationsAndrea Cavalli
Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, 40126 Bologna (Italy), Fax: (+39) 0512099734
5 shared publications
Latest Publications
- 18 December 2023
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (1) , 1-7
Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot” Topic
- 18 December 2023
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (1) , 1-7
Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot” Topic
- 18 December 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (24) , 16457-16463
Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot” Topic
- 18 December 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (24) , 16457-16463
Diagnostic and Therapeutic Radiopharmaceuticals: A “Hot” Topic
- Open Access
- 27 July 2023
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 123 (15) , 9718
Correction to “Radiosynthesis, Preclinical and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds”
- 27 July 2023
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 123 (15) , 9718
Open AccessCorrection to “Radiosynthesis, Preclinical and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds”
- Open Access
- 14 March 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (6) , 4271
Correction to “A Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases”
- 14 March 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (6) , 4271
Open AccessCorrection to “A Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases”
- Open Access
- 14 February 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (4) , 2330-2346
A Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases
The excitatory amino acid transporter 2 (EAAT2) plays a key role in the clearance and recycling of glutamate - the major excitatory neurotransmitter in the mammalian brain. EAAT2 loss/dysfunction triggers a cascade of neurodegenerative events, comprising glutamatergic excitotoxicity and neuronal death. Nevertheless, our current knowledge regarding EAAT2 in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD), is restricted to post-mortem analysis of brain tissue and experimental models. Thus, detecting EAAT2 in the living human brain might be crucial to improve diagnosis/therapy for ALS and AD. This perspective article describes the role of EAAT2 in physio/pathological processes and provides a structure-activity relationship of EAAT2-binders, bringing two perspectives: therapy (activators) and diagnosis (molecular imaging tools).
- 14 February 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (4) , 2330-2346
Open AccessA Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases
The excitatory amino acid transporter 2 (EAAT2) plays a key role in the clearance and recycling of glutamate - the major excitatory neurotransmitter in the mammalian brain. EAAT2 loss/dysfunction triggers a cascade of neurodegenerative events, comprising glutamatergic excitotoxicity and neuronal death. Nevertheless, our current knowledge regarding EAAT2 in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD), is restricted to post-mortem analysis of brain tissue and experimental models. Thus, detecting EAAT2 in the living human brain might be crucial to improve diagnosis/therapy for ALS and AD. This perspective article describes the role of EAAT2 in physio/pathological processes and provides a structure-activity relationship of EAAT2-binders, bringing two perspectives: therapy (activators) and diagnosis (molecular imaging tools).
- Open Access
- 18 November 2022
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 123 (1) , 105-229
Radiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds
- 18 November 2022
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 123 (1) , 105-229
Open AccessRadiosynthesis, Preclinical, and Clinical Positron Emission Tomography Studies of Carbon-11 Labeled Endogenous and Natural Exogenous Compounds
- 19 September 2022
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 5 (10) , 835-837
Diagnostic and Therapeutic Radiopharmaceuticals
- 19 September 2022
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 5 (10) , 835-837
Diagnostic and Therapeutic Radiopharmaceuticals
- 15 September 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (19) , 12497-12499
Diagnostic and Therapeutic Radiopharmaceuticals
- 15 September 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (19) , 12497-12499
Diagnostic and Therapeutic Radiopharmaceuticals
- 2 August 2022
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 112-113, 66-67
Perspectives on nuclear chemistry, radiochemistry, PET/SPECT imaging and radiotherapy
- 2 August 2022
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 112-113, 66-67
Perspectives on nuclear chemistry, radiochemistry, PET/SPECT imaging and radiotherapy
- Open Access
- 9 October 2021
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 6 (1) , 1-16
EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality
This guideline on molar activity (Am) and specific activity (As) focusses on small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic applications. In this guideline we describe the definition of Am and As, and how these measurements must be standardised and harmonised. Selected examples highlighting the importance of Am and As in imaging studies of saturable binding sites will be given, and the necessity of using appropriate materials and equipment will be discussed. Furthermore, common Am pitfalls and remedies are described. Finally, some aspects of Am in relation the emergence of a new generation of highly sensitive PET scanners will be discussed.
- 9 October 2021
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 6 (1) , 1-16
Open AccessEANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality
This guideline on molar activity (Am) and specific activity (As) focusses on small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic applications. In this guideline we describe the definition of Am and As, and how these measurements must be standardised and harmonised. Selected examples highlighting the importance of Am and As in imaging studies of saturable binding sites will be given, and the necessity of using appropriate materials and equipment will be discussed. Furthermore, common Am pitfalls and remedies are described. Finally, some aspects of Am in relation the emergence of a new generation of highly sensitive PET scanners will be discussed.